Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immuron Limited ( (AU:IMC) ) has shared an update.
Immuron Limited has announced senior leadership changes, with long-serving Chief Financial Officer and Company Secretary Phillip Hains stepping down from both roles effective 9 February 2026. The board acknowledged his contribution since 2013, marking the end of a key financial stewardship period for the biopharmaceutical group.
The company has appointed Olga Smejkalova as Company Secretary and primary contact for ASX communications, and Aaron Laurita as Chief Financial Officer, both effective immediately. These appointments bring additional governance, compliance, and commercial finance expertise to Immuron, potentially strengthening its corporate oversight as it advances its antibody-based therapies and Travelan franchise in global markets.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for inflammatory-mediated and infectious diseases. Its lead product, Travelan, is an orally administered passive immunotherapy aimed at reducing the risk of travelers’ diarrhea and other minor gastrointestinal disorders, sold as a listed medicine in Australia, a licensed natural health product in Canada, and a dietary supplement in the U.S.
YTD Price Performance: -16.67%
Average Trading Volume: 1,073,532
Technical Sentiment Signal: Sell
Current Market Cap: A$9.8M
For an in-depth examination of IMC stock, go to TipRanks’ Overview page.